Skip to main content
. Author manuscript; available in PMC: 2018 Sep 4.
Published in final edited form as: Expert Rev Anticancer Ther. 2017 Dec 19;18(2):131–148. doi: 10.1080/14737140.2018.1417844

Table 1.

Pancreatic cancer GEMMs and PDXs

Mouse Models Mutation Ref
Genetically engineered mouse models (GEMMS)
Genetically engineered mouse models (GEMMS)
PDX-1-Cre/Lox-Stop-Lox (LSL)-Kras or p48/LSL-Kras		 K-ras mutation in pancreatic cells [13]
PDX-1-Cre, LSL-KrasG12D, LSL-Trp53R172H/- K-ras and p53 mutations [92]
PDX-1-Cre, Brca2F11, LSL-KrasG12D, Trp53 F2–10 K-ras, BRCA2, and p53 mutations [93]
Mist1 KrasG12D/+ transgenic model KrasG12D into ORF of Mist1 [95]
PDX1-Cre, KrasG12D, Ink4a/Arfflox/flox transgenic model K-ras and Ink4a mutations [96]
PDX1-Cre, KrasG12D, Smad4flox/flox transgenic model K-ras and Smad4 mutations [97]
Ptf1acre/+, LSL-KrasG12D/+, Tgfbr2flox/flox transgenic model K-ras and TGF-β mutations [98]
LSL-KrasG12D; LSL-Trp53R172H/+; Ink4flox/+; K-ras, p53, and Ink4 [99]
Ptf1/p48-Cre mutations
Patient derived Xenografts (PDXs)
TM00310 K-ras and p53 mutations [100]
TM00312 p53 mutation [100]
TM00314 K-ras mutation [100]
More PDX models can been found in Mouse Tumor Biology Database [100]